

PART B - FEE(S) TRANSMITTAL >

this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

27916

7590

08/22/2005

VERTEX PHARMACEUTICALS INC. 130 WAVERLY STREET CAMBRIDGE, MA 02139-4242

11/22/2005 TBESHAH2 00000095 500725 10688613

01 FC:1501 02 FC:1504

1400.00 DA 300.00 DA Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fec(s) Transminal is being deposited with the United States Fortal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Lisa Romano	(Depositor's name)
	(Signature)
November 21, 2005	(Date)

APPLICATION NU.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/688,613	10/17/2003	Michael Hale	VPI/00-102 CON DIV3	2448
			US	

TITLE OF INVENTION: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FES	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	МО	\$1400	\$300	\$1700	11/22/2005	
EXAMI	NER	ART UNIT	CLASS-SUBCLASS	7		
LAMBKIN, D	EBORAH C	1626	514-422000			
I. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Tec Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.		Correspondence or age (2) the register of a Courtement 2 register 2 register 12 register 1	printing on the patent front page, names of up to 3 registered patents OR, elementary, name of a single firm (having as red attorney or agent) and the natered patent altorneys or agents. In name will be printed.	a member a mes of up to	n R. Brown x Pharmaceutic porated	
		E PRINTED ON THE PAT				
PLEASE NOTE: Unless recordation as set forth in	un assignee is identified be 37 CFR 3.11. Completion	clow, no assignee data will of this form is NOT a subsch	appear on the patent. If an assignment.	mee is identified below, the	document has been filed for	
(A) NAME OF ASSIGNE	E	(B) RESIDI	INCE: (CITY and STATE OR CO	OUNTRY)		
Vertex Ph	rmaceuticals	· Canh	ridge, Massachuse	etts 02139		
Incorporat			.			
Please check the appropriate		ries (will not be printed on t	ne patent) : 🚨 Individual 🟛 (Corporation or other private g	group entity 🚨 Governmen	
4a. The following fee(s) are o	mclosed:	4b. Paymen	of Fac(s):			
Issue Fee		A ch	ck in the amount of the foc(s) is	molosed.		
Publication Fee (No small entity discount permitted)		od) 🚨 Pвуπ	Payment by credit card. Form PTO-2038 is attached.			
Advance Order - # of Copies		The Deposit	The Director is hereby authorized by charge the required fer(s), or credit any overpayment, to Deposit Account Number 50-0725 (enclose an extra copy of this form).			
••	AALL ENTITY stams. See	37 CFR 1.27. В ь. Ар	plicant is no longer claiming SMA			
The Director of the USPTO i NOTE: The Issue Fee and Pu interest as shown by the reco	s requested to apply the Issi blication Fee (if required) v rds of the United States Par	ne Fee and Publication Fee (will not be accepted from an ent and Trademark Office.	f any) or to re-apply any previou cone other than the applicant; a re-	sly paid issue fee to the appli gistered attorney or agent; or	the assignee or other party i	
Authorized Signature	Kaun E. 7	Srow-	Date N	ovember 21, 200	5	
Typed or printed name	Karen E. Bro	wn.	Registratio	m No43,866		
	ly is governed by 35 U.S.C plication form to the USPT for reducing this burden, s rin 22313-1450. DO NOT		red to obtain or retain a benefit by collection is estimated to take 1. g upon the individual case. Any turnation Officer, U.S. Patent an TED FORMS TO THIS ADDRE			
Under the Paperwork Reduct						



Vertex Pharmaceuticals Incorporated 130 Waverly Street • Cambridge, MA 02139-4242

Tel. 617.444.6100 - Fax 617.444.6483

http://www.vrtx.com

Fax Message

TO:	Examiner: Deborah C. Lambkin
APPLICATION NO.:	10/688,613
CONFIRMATION NO.:	2448
GROUP ART UNIT.:	1626
FAX:	(571) 273-2885
FROM:	Karen E. Brown
DATE:	November 21, 2005
SUBJECT:	Attorney Docket No. VPI/00-102 CON DIV 3 US
TOTAL # OF PAGES:	3

Message or Comment:

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence, and any documents referred to as attached hereto, is being facsimile transmitted to the United States Patent and Trademark Office, on November 21, 2005.

If any problems occur with this fax transmittal, please call (617) 444-6164 immediately.

FAX Number (617) 444-6483 Legal Department

CONFIDENTIALITY NOTICE

The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information and the documents transmitted by this telecopy are phylleged and contain confidential information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. The Information intended only for the person (s) names above. The Information intended only for the person (s) names above. Any The Information intended only for the person (s) names above. The Information intended only for the person (s) names above. The Information intended only for the person (s) names above. The Information intended only for the person (s) names above. The Information intended only for the person (s) names above. Th